Genetic and ethnic modulation of cardiovascular toxicity of vascular endothelial growth factor inhibitors

Area of Science:

• Oncology
• Cardiology
• Pharmacology

Background:

• Vascular endothelial growth factor (VEGF) inhibitors are crucial anticancer agents targeting tumor angiogenesis.
• These inhibitors, including monoclonal antibodies and tyrosine kinase inhibitors (TKIs), have known cardiovascular implications.

Purpose of the Study:

• To review the cardiovascular toxicity of VEGF inhibitors.
• To explore the mechanisms underlying these adverse effects.
• To clarify the role of genetic and ethnic factors in VEGF inhibitor-induced cardiovascular toxicity.

Main Methods:

• Literature review of studies on VEGF inhibitors and cardiovascular toxicity.
• Analysis of mechanisms including endothelial dysfunction, altered vasoreactivity, and cardiomyocyte apoptosis.
• Examination of genetic and geographic data for predictive or prognostic factors.

Main Results:

• VEGF inhibitors disrupt vascular homeostasis, impairing vasodilation and vasoconstriction.
• Key cardiovascular toxicities include hypertension, heart failure, thromboembolism, and arrhythmia.
• Genetic polymorphisms are implicated as potential predictors of cardiovascular toxicity.

Conclusions:

• VEGF inhibitors pose significant cardiovascular risks by interfering with VEGF signaling pathways.
• Understanding these mechanisms and individual genetic predispositions is vital for managing patient safety.
• Further research into genetic factors can personalize cancer therapy and mitigate cardiovascular adverse events.